These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26342028)

  • 1. Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults.
    Seng KY; Hee KH; Soon GH; Chew N; Khoo SH; Lee LS
    J Antimicrob Chemother; 2015 Dec; 70(12):3298-306. PubMed ID: 26342028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
    Zvada SP; Denti P; Donald PR; Schaaf HS; Thee S; Seddon JA; Seifart HI; Smith PJ; McIlleron HM; Simonsson US
    J Antimicrob Chemother; 2014 May; 69(5):1339-49. PubMed ID: 24486870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
    Aruldhas BW; Hoglund RM; Ranjalkar J; Tarning J; Mathew SK; Verghese VP; Bose A; Mathew BS
    Br J Clin Pharmacol; 2019 Mar; 85(3):644-654. PubMed ID: 30588647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
    Chirehwa MT; McIlleron H; Wiesner L; Affolabi D; Bah-Sow O; Merle C; Denti P;
    J Antimicrob Chemother; 2019 Jan; 74(1):139-148. PubMed ID: 30239829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid.
    Marsot A; Ménard A; Dupouey J; Muziotti C; Guilhaumou R; Blin O
    Br J Clin Pharmacol; 2017 May; 83(5):1039-1047. PubMed ID: 27813241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol.
    Mlotha R; Waterhouse D; Dzinjalamala F; Ardrey A; Molyneux E; Davies GR; Ward S
    J Antimicrob Chemother; 2015; 70(6):1798-803. PubMed ID: 25759035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
    Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
    Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.
    Saktiawati AM; Sturkenboom MG; Stienstra Y; Subronto YW; Sumardi ; Kosterink JG; van der Werf TS; Alffenaar JW
    J Antimicrob Chemother; 2016 Mar; 71(3):703-10. PubMed ID: 26661397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Population Pharmacokinetics of Rifampicin in Japanese Pulmonary Tuberculosis Patients.
    Nishimura T; Kohno H; Nagai H; Maruoka D; Koike Y; Kobayashi M; Atsuda K
    Drug Res (Stuttg); 2020 May; 70(5):199-205. PubMed ID: 32193878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.
    Pouplin T; Bang ND; Toi PV; Phuong PN; Dung NH; Duong TN; Caws M; Thwaites GE; Tarning J; Day JN
    BMC Infect Dis; 2016 Apr; 16():144. PubMed ID: 27039088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
    Schall R; Müller FO; Duursema L; Groenewoud G; Hundt HK; Middle MV; Mogilnicka EM; Swart KJ
    Arzneimittelforschung; 1995 Nov; 45(11):1236-9. PubMed ID: 8929247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of examination in healthy volunteers of rifampicin and isoniazid bioavailability from Polish two-drug combination capsules of rifamazid used for tuberculosis treatment].
    Zofia Z; Niemirowska-Mikulska H; Augustynowicz-Kopeć E; Stambrowska A
    Pneumonol Alergol Pol; 1998; 66(3-4):198-206. PubMed ID: 9857665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    BMC Infect Dis; 2015 Mar; 15():126. PubMed ID: 25887748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.
    Svensson EM; Murray S; Karlsson MO; Dooley KE
    J Antimicrob Chemother; 2015 Apr; 70(4):1106-14. PubMed ID: 25535219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid.
    Requena-Méndez A; Davies G; Waterhouse D; Ardrey A; Jave O; López-Romero SL; Ward SA; Moore DAJ
    J Antimicrob Chemother; 2019 Feb; 74(2):416-424. PubMed ID: 30412245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.